Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
Active, not recruiting · NCT05463224 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients | non-small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-07-28 | NCT05463224 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sehhoon Park | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea | 1 |